RecruitingNot ApplicableNCT06445439

Optimal Pacing Rate for Cardiac Resynchronization Therapy

Optimal Pacing Rate for Cardiac Resynchronization Therapy After Atrioventricular Node Ablation in Persistent Atrial Fibrillation and Heart Failure


Sponsor

Medstar Health Research Institute

Enrollment

60 participants

Start Date

Dec 19, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria8

  • Age 18 years or older
  • History of persistent or permanent atrial fibrillation
  • Implantation of CRT or conduction system pacing in prior 3 months to 5 years of study start
  • History of intrinsic AVN block or have undergone AVN ablation in prior 3 months to 5 years of study start
  • LVEF ≥ 50%
  • N-terminal pro-B-type natriuretic peptide (NT-proBNP) \>400 pg/mL in the last 24 months
  • Clinical HF diagnosis or NYHA class II or higher
  • Able to provide informed consent

Exclusion Criteria22

  • LVEF \<50%
  • Wide QRS (greater than 150ms)
  • Isolated RV pacing
  • Severe valvular disease
  • Severe coronary artery disease as defined by one of the following:
  • ACS or PCI within 1 year
  • Any angina (CCS class 1+)
  • Unrevascularizable severe CAD (\>70% stenosis in 1+ major vessels and/or based on functional assessment)
  • ESRD
  • Significant primary pulmonary disease on home oxygen
  • Major orthopedic issues, such as being wheelchair bound and/or unable to perform a six-minute walk test
  • Ventricular ectopy \>15% premature ventricular contractions (PVC)
  • End stage cancer diagnosis
  • Life expectancy less than one year
  • Palliative or hospice care
  • Hypertrophic cardiomyopathy (HCM)
  • Uncorrected ventricular septal defect
  • Infiltrative cardiomyopathy (CM)
  • Uncontrolled hypertension as defined by blood pressure \>160/100 mm Hg on two measurements ≥15 minutes apart
  • Hemoglobin \<7 g/dL
  • Age \>90 years old
  • Pregnant or intends to become pregnant

Interventions

DEVICEPacing rate of 80 bpm

Pacing rate of 80 bpm

DEVICEPacing rate of 60 bpm

Pacing rate of 60 bpm


Locations(5)

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, United States

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

MedStar Union Memorial Hospital

Baltimore, Maryland, United States

MedStar Southern Maryland Hospital

Clinton, Maryland, United States

MedStar Heart and Vascular Office at Fairfax

Fairfax, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06445439


Related Trials